Gentherm (THRM) Q3 2024 earnings summary

Executive summary

• Secured $600 million in new automotive business awards in Q3, on track for over $2 billion in annual awards, with a win rate exceeding 80%.

• Launched 30 automotive solutions across 11 OEMs, including first ClimateSense launch on Cadillac Escalade IQ and first ComfortScale award with General Motors.

• Medical segment delivered double-digit revenue growth year-over-year, driven by Blanketrol and Astopad sales in the U.S. and Europe.

• Focused on operational execution, margin expansion, and innovation with proprietary products like ClimateSense, WellSense, and ComfortScale.

• Completed transition of production from South Carolina to Monterrey, Mexico, and sale of Greenville facility, contributing a $1.7 million gain.

Financial highlights

• Q3 2024 product revenues increased 1.5% year-over-year to $371.5 million; nine-month revenues were $1.10 billion, flat versus prior year.

• Gross margin improved to 25.5% from 23.5% year-over-year, driven by cost reductions and operational efficiencies.

• Adjusted EBITDA was $48.1 million (12.9% margin), and adjusted diluted EPS was $0.75, up from $0.64.

• Net income for Q3 2024 was $16.0 million; net income margin was 4.3%.

• Operating income rose to $32.3 million from $23.7 million year-over-year.

Outlook and guidance

• 2024 product revenue guidance revised to $1.45–$1.47 billion due to lower light vehicle production and supply chain adjustments.

• Adjusted EBITDA margin expected near midpoint of 12.5%–13.5%; effective tax rate guidance 26%–29%.

• Capital expenditures guidance unchanged at $65–$75 million.

• Guidance assumes light vehicle production in key markets will decline low to mid-single digits for 2024.

• Management believes current liquidity and cash flows are adequate for at least the next twelve months.